Literature DB >> 25286906

New options for the adjuvant treatment of cutaneous melanoma?

Amy M Weise1, Lawrence E Flaherty.   

Abstract

High-dose interferon is the current standard of care for the adjuvant treatment of high-risk cutaneous melanoma. Despite numerous clinical trials using interferon in a variety of doses and schedules, none have demonstrated a meaningful clinical improvement relative to standard high-dose interferon. Recently however, a phase III trial using biochemotherapy demonstrated a superior relapse-free survival benefit over standard interferon. In addition, several agents approved for use in metastatic melanoma are being investigated in the adjuvant setting.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25286906     DOI： 10.1007/s11912-014-0409-x

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  15 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma.

Authors:  Karlijn Koers; Anne Brecht Francken; John B A G Haanen; Leonie A E Woerdeman; Jos A van der Hage
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544

Review 3.  Staging and prognosis of cutaneous melanoma.

Authors:  Paxton V Dickson; Jeffrey E Gershenwald
Journal:  Surg Oncol Clin N Am       Date:  2011-01       Impact factor: 3.495

4.  Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.

Authors:  Alexander M M Eggermont; Stefan Suciu; Rona MacKie; Wlodzimierz Ruka; Alessandro Testori; Wim Kruit; Cornelis J A Punt; Michelle Delauney; François Sales; Gerard Groenewegen; Dirk J Ruiter; Izabella Jagiello; Konstantin Stoitchkov; Ulrich Keilholz; Danielle Lienard
Journal:  Lancet       Date:  2005-10-01       Impact factor: 79.321

5.  High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

Authors:  J M Kirkwood; J G Ibrahim; V K Sondak; J Richards; L E Flaherty; M S Ernstoff; T J Smith; U Rao; M Steele; R H Blum
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

6.  Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year--a Hellenic Cooperative Oncology Group study.

Authors:  Helen Gogas; Dimitrios Bafaloukos; John Ioannovich; Dimosthenis Skarlos; Aris Polyzos; George Fountzilas; Haralambos P Kalofonos; Gerassimos Aravantinos; Dimosthenis Tsoutsos; Petros Panagiotou; Konstantina Frangia; Theodora Petrakopoulou; Dimitrios Pectasides
Journal:  Anticancer Res       Date:  2004 May-Jun       Impact factor: 2.480

7.  Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

Authors:  Alexander M M Eggermont; Stefan Suciu; Mario Santinami; Alessandro Testori; Wim H J Kruit; Jeremy Marsden; Cornelis J A Punt; François Salès; Martin Gore; Rona Mackie; Zvonko Kusic; Reinhard Dummer; Axel Hauschild; Elena Musat; Alain Spatz; Ulrich Keilholz
Journal:  Lancet       Date:  2008-07-12       Impact factor: 79.321

8.  A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.

Authors:  John M Kirkwood; Judith Manola; Joseph Ibrahim; Vernon Sondak; Marc S Ernstoff; Uma Rao
Journal:  Clin Cancer Res       Date:  2004-03-01       Impact factor: 12.531

9.  A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence.

Authors:  Kevin B Kim; Sewa S Legha; Rene Gonzalez; Clay M Anderson; Marcella M Johnson; Ping Liu; Nicholas E Papadopoulos; Omar Eton; Carl Plager; Antonio C Buzaid; Victor G Prieto; Wen-Jen Hwu; Angela M Frost; Gladys Alvarado; Patrick Hwu; Merrick I Ross; Jeffrey E Gershenwald; Jeffrey E Lee; Paul F Mansfield; Robert S Benjamin; Agop Y Bedikian
Journal:  Melanoma Res       Date:  2009-02       Impact factor: 3.599

10.  Final version of 2009 AJCC melanoma staging and classification.

Authors:  Charles M Balch; Jeffrey E Gershenwald; Seng-Jaw Soong; John F Thompson; Michael B Atkins; David R Byrd; Antonio C Buzaid; Alistair J Cochran; Daniel G Coit; Shouluan Ding; Alexander M Eggermont; Keith T Flaherty; Phyllis A Gimotty; John M Kirkwood; Kelly M McMasters; Martin C Mihm; Donald L Morton; Merrick I Ross; Arthur J Sober; Vernon K Sondak
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544
View more
  3 in total

Review 1.  Combination or single-agent ipilimumab as immunotherapy of advanced melanoma: a critical review.

Authors:  Omar Abdel-Rahman
Journal:  Melanoma Manag       Date:  2016-08-22

2.  Doublet BRAF/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published data.

Authors:  O Abdel-Rahman; H ElHalawani; H Ahmed
Journal:  Clin Transl Oncol       Date:  2015-10-30       Impact factor: 3.405

Review 3.  Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy.

Authors:  Ruan F V Medrano; Aline Hunger; Samir Andrade Mendonça; José Alexandre M Barbuto; Bryan E Strauss
Journal:  Oncotarget       Date:  2017-07-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.